Skip to main content
. 2019 Jan-Feb;45(1):127–136. doi: 10.1590/S1677-5538.IBJU.2018.0171

Table 1. Clinical and pathological stage.

Clinical stage Patients
cT1c N0/N× M0 38 (73.1%)
cT2a N0/N× M0 8 (15,4%)
cT2b N0/N× M0 3 (5.8%)
cT2c N0/N× M0 1 (1.9%)
cT3b N0/N× M0 2 (3.8%)
Patological stage Patients
pT2a N0 M0 14 (26.9%)
pT2b N0 M0 20 (38.5%)
pT2c N0 M0 8 (15.4%)
pT3a N0 M0 5 (9.6%)
pT3b N0 M0 4 (7.7%)
pT3b N1 M0 1 (1.9%)
Pathological Gleason score Patients
Gleson 6 22 (42.3%)
Gleason 7 (3+4) 18 (34.6%)
Gleason 7 (4+3) 10 (19.2%)
Gleason 8 2 (3.9%)